CDEK
← All organizations

Dyax

For profitContributed to NME

Also known as: Dyax Corp. | DYAX CORP.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Apr 1, 2007

First marketed drug

Dec 1, 2009

First NDA

Aug 23, 2018

Last known activity

Mar 3, 2016

Acquired by Shire → Takeda on Jan 22, 2016

Timeline

1980s

  1. Jan 1, 1989

    Dyax— Founded

1990s

  1. Jan 1, 1999

    Target Quest, BV— Acquired

2010s

  1. Jan 22, 2016

    Shire— Acquired By

  2. Aug 23, 2018

    lanadelumab— Marketing Organization

  3. Aug 23, 2018

    lanadelumab— NDA Organization

  4. Dec 3, 2018

    Takeda— Now

Drugs by trial phase (3 distinct, 7 trials)

Phase 3 (3 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (7)

Details

Founded
Burlington, MA, US Jan 1, 1989
First NDA
Aug 23, 2018
Last known activity
Mar 3, 2016

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy

Notes

Acquired by Shire 2 Nov 2015